Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Reed, Shelby D
Friedman, Joëlle Y
Velazquez, Eric J
Gnanasakthy, Ari
Califf, Robert M
and
Schulman, Kevin A
2004.
Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
American Heart Journal,
Vol. 148,
Issue. 1,
p.
122.
REED, SHELBY D.
RADEVA, JASMINA I.
GLENDENNING, G. ALASTAIR
SAAD, FRED
and
SCHULMAN, KEVIN A.
2004.
COST-EFFECTIVENESS OF ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL COMPLICATIONS IN PATIENTS WITH PROSTATE CANCER.
Journal of Urology,
Vol. 171,
Issue. 4,
p.
1537.
Radeva, Jasmina I.
Reed, Shelby D.
Kaló, Zoltán
Kauf, Teresa L.
Cantu, Edward
Cretin, Nathalie
and
Schulman, Kevin A.
2005.
Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation.
Clinical Transplantation,
Vol. 19,
Issue. 1,
p.
122.
Reed, Shelby D.
Radeva, Jasmina I.
Weinfurt, Kevin P.
McMurray, John J.V.
Pfeffer, Marc A.
Velazquez, Eric J.
Allsbrook, Jennifer S.
Masselink, Leah E.
Sellers, Mary Ann
Califf, Robert M.
and
Schulman, Kevin A.
2005.
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
American Heart Journal,
Vol. 150,
Issue. 2,
p.
323.
Reed, Shelby D.
Radeva, Jasmina I.
Glendenning, G Alastair
Coleman, Robert E.
and
Schulman, Kevin A.
2005.
Economic Evaluation of Zoledronic Acid Versus Pamidronate for the Prevention of Skeletal-Related Events in Metastatic Breast Cancer and Multiple Myeloma.
American Journal of Clinical Oncology,
Vol. 28,
Issue. 1,
p.
8.
Ramsey, Scott
Willke, Richard
Briggs, Andrew
Brown, Ruth
Buxton, Martin
Chawla, Anita
Cook, John
Glick, Henry
Liljas, Bengt
Petitti, Diana
and
Reed, Shelby
2005.
Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report.
Value in Health,
Vol. 8,
Issue. 5,
p.
521.
Mishra, V
Andresen, S
Brinch, L
Kvaløy, S
Ernst, P
Lønset, M K
Tangen, J M
Wikelund, J
Flatum, C
Baggerød, E
Helle, B
Vaaler, S
and
Hagen, T P
2005.
Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study.
Bone Marrow Transplantation,
Vol. 35,
Issue. 12,
p.
1149.
Reed, Shelby D
Radeva, Jasmina I
Daniel, Davey B
Mody, Samir H
Forlenza, Jamie B
McKenzie, R Scott
and
Schulman, Kevin A
2006.
Economic Evaluation of Weekly Epoetin Alfa versus Biweekly Darbepoetin Alfa for Chemotherapy-Induced Anaemia.
PharmacoEconomics,
Vol. 24,
Issue. 5,
p.
479.
Kauf, Teresa L.
Velazquez, Eric J.
Crosslin, David R.
Weaver, W. Douglas
Diaz, Rafael
Granger, Christopher B.
McMurray, John J.V.
Rouleau, Jean-Lucien
Aylward, Philip E.
White, Harvey D.
Califf, Robert M.
and
Schulman, Kevin A.
2006.
The cost of acute myocardial infarction in the new millennium: Evidence from a multinational registry.
American Heart Journal,
Vol. 151,
Issue. 1,
p.
206.
Schulman, Kevin A.
Glick, Henry A.
and
Polsky, Daniel
2006.
Textbook of Pharmacoepidemiology.
p.
333.
Bramkamp, Matthias
Radovanovic, Dragana
Erne, Paul
and
Szucs, Thomas D.
2007.
Determinants of Costs and the Length of Stay in Acute Coronary Syndromes: A Real Life Analysis of More Than 10 000 Patients.
Cardiovascular Drugs and Therapy,
Vol. 21,
Issue. 5,
p.
389.
Patterson, Mark E.
Grant, William C.
Glickman, Seth W.
Massie, Barry M.
Ammon, Susan E.
Armstrong, Paul W.
Cleland, John G.F.
Collins, Joseph F.
Teo, Koon K.
Schulman, Kevin A.
and
Reed, Shelby D.
2009.
Resource Use and Costs of Treatment With Anticoagulation and Antiplatelet Agents: Results of the WATCH Trial Economic Evaluation.
Journal of Cardiac Failure,
Vol. 15,
Issue. 10,
p.
819.
Barnett, Paul G.
2009.
An Improved Set of Standards for Finding Cost for Cost-Effectiveness Analysis.
Medical Care,
Vol. 47,
Issue. 7_Supplement_1,
p.
S82.
Polsky, Daniel
and
Glick, Henry
2009.
Costing and Cost Analysis in Randomized Controlled Trials.
PharmacoEconomics,
Vol. 27,
Issue. 3,
p.
179.
Manca, Andrea
Sculpher, Mark J.
and
Goeree, Ron
2010.
The Analysis of Multinational Cost-Effectiveness Data for Reimbursement Decisions.
PharmacoEconomics,
Vol. 28,
Issue. 12,
p.
1079.
Flessa, Steffen
Moeller, Michael
Ensor, Tim
and
Hornetz, Klaus
2011.
Basing care reforms on evidence: The Kenya health sector costing model.
BMC Health Services Research,
Vol. 11,
Issue. 1,
Reed, Shelby D.
Eapen, Zubin J.
and
Schulman, Kevin A.
2011.
End Point Selection in Acute Decompensated Heart Failure Clinical Trials: Economic End Points.
Heart Failure Clinics,
Vol. 7,
Issue. 4,
p.
529.
Schulman, Kevin A.
Glick, Henry A.
Polsky, Daniel
and
Reed, Shelby D.
2012.
Pharmacoepidemiology.
p.
678.
Westerdijk, Machiel
Zuurbier, Joost
Ludwig, Martijn
and
Prins, Sarah
2012.
Defining care products to finance health care in the Netherlands.
The European Journal of Health Economics,
Vol. 13,
Issue. 2,
p.
203.
Abou-El-Enein, Mohamed
Römhild, Andy
Kaiser, Daniel
Beier, Carola
Bauer, Gerhard
Volk, Hans-Dieter
and
Reinke, Petra
2013.
Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs.
Cytotherapy,
Vol. 15,
Issue. 3,
p.
362.